AcrannoLife Genomics
Hyderabad, India· Est.
India‑based precision diagnostics firm offering non‑invasive liquid‑biopsy and RT‑LAMP tests for chronic disease and infection monitoring.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $5M
AI Company Overview
India‑based precision diagnostics firm offering non‑invasive liquid‑biopsy and RT‑LAMP tests for chronic disease and infection monitoring.
Chronic DiseaseTransplant MedicineInfectious Diseases
Technology Platform
Proprietary molecular counting platform for cfDNA/ctDNA quantification combined with RT‑LAMP for rapid nucleic‑acid detection.
Opportunities
Expansion of cfDNA panels to oncology and metabolic diseases, regulatory clearance in global markets, and strategic partnerships with hospital networks.
Risk Factors
Regulatory approval timelines, need for large‑scale clinical validation, and competition from established liquid‑biopsy and RT‑LAMP providers.
Competitive Landscape
Competes with Guardant Health, Roche, and other RT‑LAMP test manufacturers; differentiates through low‑cost, India‑made assays and organ‑specific cfDNA monitoring.